Clinical Trials

Wilson Therapeutics is committed to improving lives of patients with Wilson Disease through development of new treatment options. Our ongoing clinical trials are listed below with external links for additional information.

Phase 3 Study – Efficacy and safety of WTX101 administered for 48 weeks versus standard of care in Wilson Disease subjects
Learn more >>

Phase 2 Study – Efficacy and safety study of WTX101 in adult Wilson Disease patients
Learn more >>

Phase 2 Study – Assessment of copper parameters in Wilson Disease patients on standard of care treatment
Learn more >>

Presentation of final Phase 2 data from the Phase 2 trial with WTX101 with Professor Karl Heinz Weiss. Recording of presentation held at the EASL meeting 2017.
View here >>